CSS
ORKA

Cubist Systematic Strategies’s Oruka Therapeutics ORKA Stock Holding History

Cubist Systematic Strategies’s Portfolio ORKA Stock Details ORKA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		– Sell
-2,315
Closed -$106K – 3596
2024
Q2 		$106K Buy
+2,315
New +$92.3K ﹤0.01% 2620

Other funds holding ORKA

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
FFM
Fairmount Funds Management West Conshohocken, Pennsylvania $1.38B AUM 407.79% 1-Year Est. Return
VA
VR Adviser New York $2.68B AUM 422.73% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
CC
Commodore Capital New York $1.73B AUM 298.96% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
APM
Avidity Partners Management Dallas, Texas $936M AUM 195% 1-Year Est. Return
PBA
Paradigm Biocapital Advisors New York $4.89B AUM 251.12% 1-Year Est. Return

Cubist Systematic Strategies's ORKA Position: Q3 2024 in Review

Cubist Systematic Strategies sold out of Oruka Therapeutics (ORKA) in Q3 2024, closing a stake of 2,315 shares — an estimated $106K sold.

Cubist Systematic Strategies first reported a position in ORKA in Q2 2024 and held it in 1 quarter. The position peaked at $106K in Q2 2024. 42 funds tracked by Wall St. Rank hold ORKA as of Q3 2024.

  • Cubist Systematic Strategies reported no remaining Oruka Therapeutics position as of Q3 2024 after selling out during the quarter.
  • Cubist Systematic Strategies sold 2,315 Oruka Therapeutics shares in Q3 2024, an estimated $106K.
  • Cubist Systematic Strategies first reported a position in Oruka Therapeutics in Q2 2024 and held it in 1 quarter.
  • Cubist Systematic Strategies's Oruka Therapeutics position peaked at $106K in Q2 2024.
  • 42 funds tracked by Wall St. Rank held Oruka Therapeutics as of Q3 2024.

Based on Cubist Systematic Strategies's 13F filing for Q3 2024, filed 14 Nov 2024.